Product description

Tenofovir Disoproxil Emtricitabine Mylan 300/200 tenofovir disoproxil maleate 300 mg and emtricitabine 200 mg film coated tablets

All batches within expiry

ARTG: 265834

Prescription Medicine for:
The treatment of HIV-infected adults over the age of 18 years, in combination with other antiretroviral agents.
In combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.

See a list of details to help identify the product

Reason the product is recalled

Potential for broken and/or split tablets.

In the event a broken/split tablet is consumed, this may result in an ineffective dose if the tablet is not taken in its entirety.

The hazards to consumers

A broken or split tablet may lead to ineffective dosing, which may increase the risk of adverse health effects.

What consumers should do

Consumers that have been prescribed Tenofovir Disoproxil Emtricitabine Mylan 300/200 should consult their treating physician for advice.

Consumers that have any unexpired product should return the product to their pharmacist for a refund.

A TGA web statement can be found at https://www.tga.gov.au/alert/tenofovir-disoproxil-emtricitabine-mylan-300200

For further information, please contact Alphapharm on 1800 274 276.

Details to help identify the product

Supplier running the recall

Who sold the product

Chemists and Pharmacies

Identifying numbers

Other identifying numbers

AUST R 265834

Where the product was sold

Nationally

Print supporting information

Responsible regulators

Regulators are established or appointed by government. They enforce regulations and rules.

Quote PRA number 2020/18764 when contacting a regulator about this recall.

Recall and remedy questions

Contact the Therapeutic Goods Administration if you have:

  • a question about the remedy being offered to you by the business that is responsible for managing this recall, or
  • concerns about the way the business is managing this recall.